Identification of drug candidates and biomarkers for immunotherapy (cancer and autoimmune diseases)

IT-Targets project aims to identify innovative drugs candidates and biomarkers for cancer immunotherapy and auto-immune diseases in order to improve the response of patients to immunotherapy. The strategy is based on sampling human clinical samples, purify the different cell types and profile the expression of G protein-coupled receptors, one of the most successful target classes for drug discovery. The uniqueness of the project is based on the smart mix of world-class academic experts in tumour immunology and G protein-coupled receptors with companies having a strong focus on drug discovery in cancer immunotherapy or immune disease and diagnostic applications linked to immune cells.

Consortium:

Companies: iTeos Therapeutics, ImmunXperts, ChemCom

Universities: UCLouvain (Duve Institute), Université Libre de Bruxelles

 

Contact:

Vanessa Bol: [email protected]

Site web: http://www.iteostherapeutics.com/